US Pharma MarketingASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant even as competition mounts. To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant. Instead, the Swiss pharma has been inspired to open a new phase 3 study in the adjuvant setting. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small…
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant. Instead, the Swiss pharma has been inspired to open a new phase 3 study in the adjuvant setting.
Source: FierceBiotech